A Baltimore health technology company that has developed an app to help manage diabetes said Tuesday it has raised more than $29 million in a series B financing round, with an investment by Johnson & Johnson.
WellDoc also said it has an agreement to integrate its BlueStar app into products from Johnson & Johnson subsidiary LifeScan Inc., which monitor blood glucose levels. The goal is to create a "real-time, personalized approach for the management of Type 2 diabetes," WellDoc said.
WellDoc announced in December it had raised $22 million in series B funding, led by Samsung Ventures and Merck Global Health Innovation (GHI) Fund. The firm declined to say how much Johnson & Johnson Innovation –JJDC Inc. contributed to push the round to $29.5 million.
Founded in 2005, WellDoc employs 25 people in Baltimore and another 25 in India. A spokeswoman said the firm already has received a slew of resumes for the roughly 17 positions it expects to hire for with the new funding.